Arch Therapeutics Reports Positive Preclinical Data from Study of AC5 Surgical Hemostatic Device(TM) in Animals Treated with Brilinta(R) (ticagrelor)
November 18, 2014 08:57 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Nov 18, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostat Device™, announced that an independent...
Arch Therapeutics Will Present at Two Investor Conferences in November
November 10, 2014 08:57 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Nov 10, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™, announced that it would be...
Arch Therapeutics Reports Positive Preclinical Data From Study of AC5 Surgical Hemostatic Device(TM) in Animals Treated With the Antiplatelet Medications Plavix(R) (Clopidogrel) and Aspirin
November 06, 2014 08:57 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Nov 6, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostat Device ™, announced that an independent...
Arch Therapeutics Negotiating a Collaboration Agreement With CURAM Centre for Research in Medical Devices
October 23, 2014 08:15 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Oct 23, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostat™, announced today that it is...
Arch Therapeutics Will Present at the Livingston Securities Life Sciences Stakeholders Summit on October 1, 2014
September 30, 2014 08:57 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Sep 30, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostat™, announced that it will be featured as a...
Arch Therapeutics Co-Founder Rutledge Ellis-Behnke to Speak at 12th International Conference on Neuroprotective Agents on September 29
September 23, 2014 08:50 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Sep 23, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ for potential use in...
Arch Therapeutics Co-Founder Rutledge Ellis-Behnke to Speak at 12th Annual Current Issues in Medicine, Biotech and Pharma Conference on September 18
September 16, 2014 11:20 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Sep 16, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ for potential use in bleeding...
Arch Therapeutics Announces Positive Preclinical Data From an Independent Study of AC5 Surgical Hemostatic Device(TM) in Animals on Blood Thinners
September 08, 2014 07:57 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Sep 8, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™, announced that an independent...
Arch Therapeutics Will Present at the 2014 Aegis Capital Healthcare Conference in Las Vegas, NV September 10-13th, 2014
September 02, 2014 07:58 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Sep 2, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company") today announced it will be featured as a presenting company at the 2014 Aegis Capital...
Arch Therapeutics Will Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th, 2014
August 26, 2014 07:58 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Aug 26, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), today announced it will be featured as a presenting company at the 16th Annual Rodman...